Anebulo Pharmaceuticals (NASDAQ:ANEB – Get Free Report) will likely be posting its Q4 2026 resultson Wednesday, September 23rd. Analysts expect Anebulo Pharmaceuticals to post earnings of ($0.10) per share for the quarter. Investors can check the company’s upcoming Q4 2026 earning report page for the latest details on the call scheduled for Tuesday, September 22, 2026 at 4:00 PM ET.
Anebulo Pharmaceuticals Stock Performance
Shares of ANEB opened at $0.32 on Tuesday. The stock has a 50 day moving average price of $0.32 and a two-hundred day moving average price of $0.45. The firm has a market capitalization of $12.85 million, a P/E ratio of -1.66 and a beta of -1.82. Anebulo Pharmaceuticals has a 52 week low of $0.00 and a 52 week high of $2.85.
About Anebulo Pharmaceuticals
Anebulo Pharmaceuticals, Inc (NASDAQ: ANEB) is a clinical-stage biopharmaceutical company focused on developing treatments for acute cannabinoid intoxication and other conditions associated with cannabinoid use. The company’s work is aimed at addressing medical needs for patients experiencing severe or potentially dangerous effects from cannabis and related substances.
Anebulo’s lead product candidate, ANEB-001, is an orally administered small-molecule antagonist of the cannabinoid 1 (CB1) receptor.
Recommended Stories
- Five stocks we like better than Anebulo Pharmaceuticals
- Can Bloom Energy Pop the Top Off AI’s Massive Energy Bottleneck?
- Coach’s Momentum Powers Tapestry Despite the Stock’s Sharp Pullback
- AI Is Reshaping SaaS—These 2 Software ETFs Offer Different Ways to Play It
- Insiders Signal Deep Value In DICK’s Sporting Goods
Receive News & Ratings for Anebulo Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anebulo Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
